Healthcare resource utilization after initiation of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors or other glucose‐lowering drugs in Japanese patients with type 2 diabetes

Aim To examine healthcare resource utilization in type 2 diabetes (T2D) patients after initiation of sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is) versus dipeptidyl peptidase‐4 inhibitors (DPP‐4is) or other glucose‐lowering drugs (oGLDs). Materials and Methods A cost‐utilization analysis was...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2021-04, Vol.23 (S2), p.28-39
Main Authors: Kohsaka, Shun, Takeda, Masayoshi, Kidani, Yoko, Yajima, Toshitaka
Format: Article
Language:English
Subjects:
Costs
cost‐effectiveness
database research
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Dipeptidyl-peptidase IV
Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
DPP‐4 inhibitor
Glucose
Glucose transporter
Health Care Costs
health economics
Humans
Hypoglycemic Agents - therapeutic use
Inhibitor drugs
Japan - epidemiology
Middle Aged
Patients
Peptidase
Pharmaceutical Preparations
Resource utilization
SGLT‐2 inhibitor
Sodium
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Symporters
type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To examine healthcare resource utilization in type 2 diabetes (T2D) patients after initiation of sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is) versus dipeptidyl peptidase‐4 inhibitors (DPP‐4is) or other glucose‐lowering drugs (oGLDs). Materials and Methods A cost‐utilization analysis was performed using a nationwide hospital‐based administrative claims database (Medical Data Vision) during 2014‐2018 in Japan, where universal healthcare coverage is maintained under a single‐payer system. Data on T2D patients initiated on either SGLT‐2is or oGLDs during the study period (228 514 patients) were extracted and subjected to a 1:1 propensity score‐matching analysis (7626 patient pairs for DPP‐4is and 28 484 for oGLDs). Direct healthcare resource utilizations and inpatient and outpatient costs were compared. Results After matching, baseline characteristics were well balanced, including healthcare costs within 3 and 12 months before the index date (standardized difference 
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.14289